MAP2K7 and neoplasm: For example, tumours from patients in cluster 1 (n = 11) had significantly more mutations (8.6 vs 3.5 in all other groups) and a significant enrichment of mutations and amplifications in genes from the ERBB signalling pathway (PLCG2, MAP2K7, ERBB4, and CAMK2B).